G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.

Kaitlyn J AndreanoSuzanne E WardellJennifer G BakerTaylor K DesautelsRobert BaldiChristina A ChaoKendall A HeetderksYeeun BaeRui XiongDebra A TonettiLauren M GutgesellJiong ZhaoJessica A SorrentinoDelita A ThompsonJohn E BisiJay C StrumGregory R J ThatcherJohn D Norris

Published in: Breast cancer research and treatment (2020)

These data show that G1T48 has the potential to be an efficacious oral antineoplastic agent in ER-positive breast cancer.

Keyphrases

estrogen receptor
positive breast cancer
cell cycle
electronic health record
cell proliferation
machine learning
human health
climate change
data analysis
deep learning